Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimal clinical management of tenosynovial giant cell tumours: a UK perspective.

Bone & joint open·2026
Same author

Multidisciplinary team interpretation performance for indeterminate bone uptake on PSMA PET during prostate cancer staging: Comparison with PROMISE criteria.

European journal of nuclear medicine and molecular imaging·2026
Same author

UK guidelines for the management of bone sarcomas.

British journal of cancer·2024
Same author

A retrospective evaluation of inter-fraction motion in prostate cancer patients with involved nodes receiving prostate and pelvic ± para-aortic nodal irradiation.

Journal of medical imaging and radiation sciences·2024
Same author

UK guidelines for the management of soft tissue sarcomas.

British journal of cancer·2024
Same author

Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata.

British journal of cancer·2023
Same journal

Discrimination of plaque from sluggish-flow-related hyperintense artifact on high-resolution magnetic resonance vessel wall imaging.

European journal of radiology·2026
Same journal

MRI-based quantification of intratumoral heterogeneity for differentiating glioblastoma from solitary brain metastasis: a two-center study.

European journal of radiology·2026
Same journal

MRI/MRCP and endoscopic ultrasound in pancreatobiliary disease: defining complementary roles in diagnostic and therapeutic decision-making.

European journal of radiology·2026
Same journal

Left atrial geometry in atrial Fibrillation: A comparison between electroanatomical mapping and computed tomography.

European journal of radiology·2026
Same journal

Enhancing pancreatic imaging in CT - prospective comparison of fixed versus individualized post-trigger delay in bolus tracking.

European journal of radiology·2026
Same journal

Ultrasound elastography of the liver and spleen in postoperative monitoring after abdominal surgery: A radiological perspective.

European journal of radiology·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Uterine sarcomas--recent progress and future challenges.

Beatrice M Seddon1, Reena Davda

  • 1London Sarcoma Service, Department of Oncology, University College Hospital, 1st Floor Central, 250 Euston Road, London, NW1 2PG, United Kingdom. beatrice.seddon@uclh.nhs.uk

European Journal of Radiology
|January 21, 2011
PubMed
Summary
This summary is machine-generated.

Uterine sarcomas are rare cancers challenging to diagnose and treat. New staging and advanced therapies offer improved management for early and advanced stages, impacting patient prognosis.

More Related Videos

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Related Experiment Videos

Last Updated: Jun 5, 2026

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Area of Science:

  • Gynecologic Oncology
  • Rare Cancers
  • Sarcoma Research

Background:

  • Uterine sarcomas present diagnostic and therapeutic challenges.
  • Pre-operative radiological diagnosis is often difficult, leading to post-operative confirmation.
  • Existing staging systems have limitations in predicting prognosis.

Purpose of the Study:

  • To review current understanding and management of uterine sarcomas.
  • To discuss diagnostic difficulties and recent advancements in staging.
  • To explore treatment options for early and advanced disease, including novel therapies.

Main Methods:

  • Review of current literature on uterine sarcoma diagnosis and treatment.
  • Discussion of established and emerging therapeutic strategies.
  • Analysis of adjuvant therapies, chemotherapy, hormonal therapy, and targeted agents.

Main Results:

  • A new FIGO staging system may improve prognostic grouping.
  • Total abdominal hysterectomy is standard for early disease; role of oophorectomy/lymphadenectomy is unclear.
  • Adjuvant radiotherapy and chemotherapy lack proven overall survival benefits.
  • Advanced disease shows promise with newer agents like gemcitabine, docetaxel, and trabectedin.
  • Hormonal therapies are more effective for endometrial stromal sarcoma.
  • Targeted agents show activity in uterine sarcomas.
  • Non-pharmacological treatments are valuable for metastatic disease.

Conclusions:

  • Accurate diagnosis and staging are crucial for effective uterine sarcoma management.
  • Treatment strategies are evolving, with a focus on risk-stratified approaches.
  • Novel systemic and non-pharmacological therapies offer new hope for advanced uterine sarcomas.